Now Accepting Submissions for Novel hMSC Applications in Europe and North America

Application Deadline: May 31st, 2022

Award Total: Up to $10,000 in applicable RoosterBio® products to be used over a 12 month period

Human mesenchymal stromal cells (hMSCs) are a critical raw material for a growing number of emerging regenerative medicine (RM) applications including cell and gene therapies, engineered tissues, combination products/medical devices, and exosome / extracellular vesicle (EV) based therapies.

RoosterBio is helping to advance these technologies through innovative products and processes, which are the foundation for standardized, highly-qualified hMSC bioprocess systems. These systems enable rapid adoption of hMSCs into a therapeutic program, easy scale-up and scale-out to produce clinically relevant cell numbers, and to ultimately streamline the path from R&D to Product Development to cGMP Manufacturing & Clinical Trials. Our vision is to accelerate hMSC and exosome-based therapy development to fuel the rapid commercialization of scalable regenerative cures.

Our Objective

The RoosterBio Development Award aims to support North American or European investigators who are interested in our common goals in emerging application areas related to hMSC-based therapeutic targets and methodologies. As such, we have identified key areas of interest in hMSC / exosome manufacturing and therapeutic application, but welcome submissions from other emerging areas.

Requested proposals for this solicitation are preferentially translationally focused early-stage, proof-of-concept, or pre-clinical in vitro or in vivo studies related to the hMSC / exosome technology space. We’re also interested in new hMSC applications that may be tailored to a specific disease model.

We ask applicants to specify their need for traditional serum-based or xeno-free (XF) reagents based on their current research design needs. Awardees will take part in a kickoff meeting to ensure alignment of material and process.

Submissions are encouraged from all areas of hMSC / exosome research, including but not limited to:

• hMSC / exosome pre-clinical therapeutic discovery
• hMSC-based genetic engineering methods and applications
• Exosome / Extracellular vesicle potency assay development
• Autologous hMSC manufacturing
• hMSC applications in longevity, oncology, or fertility
• Novel Applications in hMSC bioprocessing

  Applicants must be 18 years of age or older and be located within the United States / Canada / Europe and affiliated with an R&D lab at a University, Hospital, or Institutional setting with access to lab space for receiving products, properly storing, and executing proposed work. Awardees acknowledge/agree to RoosterBio’s standard Terms and Conditions along with additional terms outlined below.

Post Award Reporting

Recipients will be expected to provide the following output:

1. Guest Blog Post (2): One upon completion of study and may be comprised of a 15 to 30 minute interview with PI, the 2^nd highlighting a publication or presentation/poster supported by the award.
2. Communication of results of study with an informal teleconference presentation at end of 12 month period, with potential for 1 additional update upon study completion.
3. Acknowledgment of use of RoosterBio products and support from RoosterBio on all conference submissions (abstracts, posters, talks) and in any publications resulting from work conducted under this grant.

Note: please see Additional Information and Terms section Application Form here